Media

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results And Announces Clinical Program Updates

Oncopeptides publishes final outcome in the fully guaranteed rights issue

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Vicore Pharma – Interim report January-March 2024

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab

BONESUPPORT HOLDING AB (publ) – publishes Q1 2024 Interim report

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2023 Annual Report has been published.

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT